These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 36609982)

  • 1. Conditional Funding Recommendations for Drugs in Canada: A Cross-Sectional Analysis.
    Graili P
    Appl Health Econ Health Policy; 2023 Jul; 21(4):673-681. PubMed ID: 36609982
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Health technology assessment of drugs for rare diseases: insights, trends, and reasons for negative recommendations from the CADTH common drug review.
    Janoudi G; Amegatse W; McIntosh B; Sehgal C; Richter T
    Orphanet J Rare Dis; 2016 Dec; 11(1):164. PubMed ID: 27908281
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Health technology assessment and price negotiation alignment for rare disorder drugs in Canada: Who benefits?
    Rawson NSB
    Orphanet J Rare Dis; 2022 Jun; 17(1):218. PubMed ID: 35698235
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Impact of Regulatory Approval Status on CADTH Reimbursement of Oncology Drugs and Role of Real-World Evidence on Conditional Approvals from 2019 to 2021.
    Lau C; Dranitsaris G
    Curr Oncol; 2022 Oct; 29(11):8031-8042. PubMed ID: 36354695
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Health Technology Assessment Process for Oncology Drugs: Impact of CADTH Changes on Public Payer Reimbursement Recommendations.
    Binder L; Ghadban M; Sit C; Barnard K
    Curr Oncol; 2022 Mar; 29(3):1514-1526. PubMed ID: 35323327
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Reimbursement recommendations for cancer drugs supported by phase II evidence in Canada.
    Li YYR; Mai H; Trudeau ME; Mittmann N; Chiasson K; Chan KKW; Cheung MC
    Curr Oncol; 2020 Oct; 27(5):e495-e500. PubMed ID: 33173389
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The impact of willingness-to-pay threshold on price reduction recommendations for oncology drugs: a review of assessments conducted by the Canadian Agency for Drugs and Technologies in Health.
    Balijepalli C; Gullapalli L; Joshy J; Rawson NS
    J Comp Eff Res; 2024 May; 13(5):e230178. PubMed ID: 38567953
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Appraisals by Health Technology Assessment Agencies of Economic Evaluations Submitted as Part of Reimbursement Dossiers for Oncology Treatments: Evidence from Canada, the UK, and Australia.
    Ball G; Levine MAH; Thabane L; Tarride JE
    Curr Oncol; 2022 Oct; 29(10):7624-7636. PubMed ID: 36290879
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Common drug review recommendations for orphan drugs in Canada: basis of recommendations and comparison with similar reviews in Quebec, Australia, Scotland and New Zealand.
    McCormick JI; Berescu LD; Tadros N
    Orphanet J Rare Dis; 2018 Jan; 13(1):27. PubMed ID: 29382371
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Patients' perspectives can be integrated in health technology assessments: an exploratory analysis of CADTH Common Drug Review.
    Berglas S; Jutai L; MacKean G; Weeks L
    Res Involv Engagem; 2016; 2():21. PubMed ID: 29062521
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Health-related quality of life in oncology drug reimbursement submissions in Canada: A review of submissions to the pan-Canadian Oncology Drug Review.
    Raymakers AJN; Regier DA; Peacock SJ
    Cancer; 2020 Jan; 126(1):148-155. PubMed ID: 31544234
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Association Between the Use of Surrogate Measures in Pivotal Trials and Health Technology Assessment Decisions: A Retrospective Analysis of NICE and CADTH Reviews of Cancer Drugs.
    Pinto A; Naci H; Neez E; Mossialos E
    Value Health; 2020 Mar; 23(3):319-327. PubMed ID: 32197727
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Factors associated with positive and negative recommendations for cancer and non-cancer drugs for rare diseases in Canada.
    Nagase FNI; Stafinski T; Sun J; Jhangri G; Menon D
    Orphanet J Rare Dis; 2019 Jun; 14(1):127. PubMed ID: 31174574
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Timeliness of Health Technology Assessments and Price Negotiations for Oncology Drugs in Canada.
    Rawson NSB; Stewart DJ
    Clinicoecon Outcomes Res; 2024; 16():437-445. PubMed ID: 38812711
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Is Canada Moving towards a More Agile Regulatory Approval and Reimbursement Process with a Shifting Role for Real-World Evidence (RWE) for Oncology Drugs?
    Lau CY; Rawson NSB
    Curr Oncol; 2024 Sep; 31(9):5599-5607. PubMed ID: 39330042
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Alignment of health technology assessments and price negotiations for new drugs for rare disorders in Canada: Does it lead to improved patient access?
    Rawson NSB
    J Popul Ther Clin Pharmacol; 2020 Feb; 27(1):e48-e64. PubMed ID: 32124580
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Closing the Gaps to Timely Patient Access: Perspectives on Conditional Funding Models.
    Glennie J; Villalba E; Wheatley-Price P
    Curr Oncol; 2022 Feb; 29(2):981-988. PubMed ID: 35200582
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
    Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
    Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Health Technology Assessment Reports for Non-Oncology Medications in Canada from 2018 to 2022: Methodological Critiques on Manufacturers' Submissions and a Comparison between Manufacturer and Canadian Agency for Drugs and Technologies in Health (CADTH) Analyses.
    Mirzayeh Fashami F; Tarride JE; Sadeghirad B; Hariri K; Peyrovinasab A; Levine M
    Pharmacoecon Open; 2024 Nov; 8(6):823-836. PubMed ID: 39103675
    [TBL] [Abstract][Full Text] [Related]  

  • 20. FDA Accelerated Approval for Malignant Hematology and Oncology Indications in the Canadian Environment.
    Ho C; Lim HJ; Regier DA
    Curr Oncol; 2022 Jan; 29(2):402-410. PubMed ID: 35200536
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.